{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:46:11Z","timestamp":1784367971727,"version":"3.55.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Viloxazine is a novel nonstimulant medication approved for the treatment of attention-deficit\/hyperactivity disorder (ADHD).<\/jats:p><\/jats:sec>Objectives<\/jats:title>To investigate the whether viloxazine is associated with effective and acceptable outcomes when treating children and adolescents with ADHD and to evaluate these outcomes\u2019 associations with viloxazine doses and duration of treatment.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>The MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, PsycINFO, and ClinicalTrial.gov databases were searched from database inception to June 23, 2024.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>Two reviewers independently screened for double-blind, fixed-dose randomized clinical trials (RCTs) that compared viloxazine with placebo for pediatric patients with ADHD.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Data extraction was completed independently by 2 authors and cross-checked for errors. Random-effects pairwise and dose-response meta-analyses were conducted.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the improvement of ADHD symptoms (measured by ADHD Rating Scale\u20135), and the secondary outcomes were all-cause discontinuation, dropout due to adverse effects, and serious adverse effects.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 5 dose-response RCTs were included, with 1560 participants (1011 [64.8%] male; mean [SD] age, 10.6 [6.7] years). Viloxazine was associated with better outcomes in ADHD treatment compared with placebo (mean difference, 5.47 points; 95% CI, 4.03-6.91 points). The dose-response curve was bell-shaped, suggesting that doses greater than 400 mg or greater than 7 mg\/kg might not be associated with more efficacy. The temporal trends analysis showed ascent curves tapering off at approximately weeks 4 to 6. The curve for 100 mg\/d declined more rapidly, while the curves for 200 mg\/d and 400 mg\/d declined more gradually. The overall discontinuation rate due to adverse effects was 4.15% in the viloxazine group (45 of 1084), while viloxazine compared with placebo was associated with 2.48-fold higher risk of discontinuation due to adverse effects (risk ratio, 2.48; 95% CI, 1.26-4.88).<\/jats:p><\/jats:sec>Conclusions and relevance<\/jats:title>In this meta-analysis, viloxazine was associated with better efficacy in treating children and adolescents with ADHD than placebo. A moderate dose (200-400 mg or 6-8 mg\/kg) may provide optimal treatment outcomes. Future studies are warranted to assess the long-term effect of viloxazine. Viloxazine was relatively well tolerated for children and adolescents with ADHD.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.45885","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:02:11Z","timestamp":1732032131000},"page":"e2445885","source":"Crossref","is-referenced-by-count":9,"title":["Response Trajectories and Temporal Trends of Viloxazine Treatment for Young People With ADHD"],"prefix":"10.1001","volume":"7","author":[{"given":"Chia-Ling","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Centre, Taipei, Taiwan"},{"name":"Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Thompson","sequence":"additional","affiliation":[{"name":"Centre for Chronic Illness and Ageing, University of Greenwich, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Stubbs","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Tao","family":"Tseng","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan"},{"name":"Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan"},{"name":"Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung, Taiwan"},{"name":"Institute of Precision Medicine, National Sun Yat-sen University, Kaohsiung City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Chi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tri-Service General Hospital, National Defense Medical Centre, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kang","family":"Tu","sequence":"additional","affiliation":[{"name":"Institute of Health Data Analytics & Statistics, College of Public Health, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Wei","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan"},{"name":"Department of Psychiatry, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Sung","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Centre, Taipei, Taiwan"},{"name":"Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"issue":"11","key":"zoi241308r1","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00787-016-0841-6","article-title":"The impact of ADHD on the health and well-being of ADHD children and their siblings.","volume":"25","author":"Peasgood","year":"2016","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"6","key":"zoi241308r2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/jcpp.12620","article-title":"Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity.","volume":"58","author":"Sibley","year":"2017","journal-title":"J Child Psychol Psychiatry"},{"issue":"6","key":"zoi241308r3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1176\/ajp.2007.164.6.942","article-title":"The worldwide prevalence of ADHD: a systematic review and metaregression analysis.","volume":"164","author":"Polanczyk","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"4","key":"zoi241308r4","doi-asserted-by":"publisher","first-page":"e994","DOI":"10.1542\/peds.2014-3482","article-title":"Prevalence of attention-deficit\/hyperactivity disorder: a systematic review and meta-analysis.","volume":"135","author":"Thomas","year":"2015","journal-title":"Pediatrics"},{"issue":"3","key":"zoi241308r5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1192\/bjp.bp.107.048827","article-title":"Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis.","volume":"194","author":"Simon","year":"2009","journal-title":"Br J Psychiatry"},{"issue":"1","key":"zoi241308r6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3934\/publichealth.2023004","article-title":"ADHD in children and adolescents: review of current practice of non-pharmacological and behavioural management.","volume":"10","author":"Ogundele","year":"2023","journal-title":"AIMS Public Health"},{"issue":"8","key":"zoi241308r7","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/17512433.2020.1796636","article-title":"An update on the clinical pharmacology of methylphenidate: therapeutic efficacy, abuse potential and future considerations.","volume":"13","author":"Shellenberg","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"zoi241308r8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4103\/2231-0738.191660","article-title":"Role of norepinephrine reuptake inhibitors in attention deficit hyperactivity disorder: A mechanism-based short review.","volume":"6","author":"Jamkhande","year":"2016","journal-title":"Int J Nutr Pharmacol Neurol Dis"},{"issue":"5","key":"zoi241308r9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3810\/pgm.2010.09.2204","article-title":"The role of alpha2-adrenergic agonists in attention-deficit\/hyperactivity disorder.","volume":"122","author":"Sallee","year":"2010","journal-title":"Postgrad Med"},{"issue":"1","key":"zoi241308r10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12888-021-03040-5","article-title":"Regional brain volume predicts response to methylphenidate treatment in individuals with ADHD.","volume":"21","author":"Chang","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"9","key":"zoi241308r11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"zoi241308r12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/17425255.2022.2103406","article-title":"Evaluating the pharmacokinetics of extended release viloxazine in the treatment of children with attention-deficit\/hyperactivity disorder.","volume":"18","author":"Childress","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"zoi241308r13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/JCP.0000000000001404","article-title":"A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit\/hyperactivity disorder.","volume":"41","author":"Nasser","year":"2021","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"zoi241308r14","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.clinthera.2020.05.021","article-title":"A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit\/hyperactivity disorder in school-age children.","volume":"42","author":"Nasser","year":"2020","journal-title":"Clin Ther"},{"issue":"2","key":"zoi241308r15","first-page":"43","article-title":"A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD.","volume":"51","author":"Nasser","year":"2021","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"zoi241308r16","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.clinthera.2021.01.027","article-title":"Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial.","volume":"43","author":"Nasser","year":"2021","journal-title":"Clin Ther"},{"issue":"5","key":"zoi241308r17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40263-023-01005-8","article-title":"Nonstimulant medications for attention-deficit\/hyperactivity disorder (ADHD) in adults: systematic review and meta-analysis.","volume":"37","author":"Radonjic","year":"2023","journal-title":"CNS Drugs"},{"key":"zoi241308r18","doi-asserted-by":"publisher","DOI":"10.1177\/11795735221092522","article-title":"Viloxazine for attention-deficit hyperactivity disorder: a systematic review and meta-analysis of randomized clinical trials.","volume":"14","author":"Singh","year":"2022","journal-title":"J Cent Nerv Syst Dis"},{"issue":"12","key":"zoi241308r19","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.3390\/brainsci13121627","article-title":"Efficacy and safety of SPN-812 (extended-release viloxazine) in children and adolescents with attention-deficit\/hyperactivity disorder: a systematic review and meta-analysis.","volume":"13","author":"Tan","year":"2023","journal-title":"Brain Sci"},{"issue":"71","key":"zoi241308r20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"zoi241308r21","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1177\/0962280218773122","article-title":"One-stage dose-response meta-analysis for aggregated data.","volume":"28","author":"Crippa","year":"2019","journal-title":"Stat Methods Med Res"},{"issue":"2","key":"zoi241308r23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/1087054719836159","article-title":"A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD.","volume":"24","author":"Johnson","year":"2020","journal-title":"J Atten Disord"},{"issue":"7","key":"zoi241308r24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40263-023-01023-6","article-title":"Extended-release viloxazine compared with atomoxetine for attention deficit hyperactivity disorder.","volume":"37","author":"Price","year":"2023","journal-title":"CNS Drugs"},{"issue":"10","key":"zoi241308r25","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1177\/1087054720903372","article-title":"Relationship between treatment duration and efficacy of pharmacological treatment for ADHD: a meta-analysis and meta-regression of 87 randomized controlled clinical trials.","volume":"25","author":"Castells","year":"2021","journal-title":"J Atten Disord"},{"key":"zoi241308r26","doi-asserted-by":"publisher","first-page":"h5203","DOI":"10.1136\/bmj.h5203","article-title":"Methylphenidate for attention-deficit\/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials.","volume":"351","author":"Storeb\u00f8","year":"2015","journal-title":"BMJ"},{"issue":"2","key":"zoi241308r27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jaac.2013.11.005","article-title":"Efficacy and safety of atomoxetine in children and adolescents with attention-deficit\/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.","volume":"53","author":"Schwartz","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"zoi241308r28","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/s41380-021-01391-9","article-title":"The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit\/hyperactivity disorder in children and adolescents: a meta-analysis.","volume":"27","author":"Farhat","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"4","key":"zoi241308r29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1177\/10870547231214988","article-title":"The dose-response relationship of atomoxetine for the treatment of children with ADHD: a systematic review and dose-response meta-analysis of double-blind randomized placebo-controlled trials.","volume":"28","author":"Terao","year":"2024","journal-title":"J Atten Disord"},{"issue":"12","key":"zoi241308r30","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/jcph.1940","article-title":"Population pharmacokinetics of viloxazine extended-release capsules in pediatric subjects with attention deficit\/hyperactivity disorder.","volume":"61","author":"Nasser","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"zoi241308r31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5455\/PBS.20210419035444","article-title":"Treatment related adverse events in children with attention-deficit\/hyperactivity disorder using atomoxetine.","volume":"11","author":"Kasar","year":"2021","journal-title":"Psychiatry and Behavioral Sciences"},{"issue":"2","key":"zoi241308r32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF00613832","article-title":"Unwanted symptoms in depressed patients treated with viloxazine: an algorithm for identification of illness-related symptoms.","volume":"24","author":"Maistrello","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"zoi241308r22","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis","author":"Harrell","year":"2015"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2826361\/yu_2024_oi_241308_1731422423.04208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:02:14Z","timestamp":1732032134000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2826361"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.45885","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]}}}